Executive Summery

Before 2025, Advil was a brand with strong product credentials and dominant presence in key geographies, but it lacked a clear and cohesive global identity, and its potential was unrealized in smaller challenger markets around the world. 

Creatively, the brand was trapped in the same codes as every other pain relief brand – with no emotional connection with consumers.  Commercially, Advil was a challenger in most markets, operating with significantly lower investment than competitors. Without a distinctive brand and with low investment, the brand was slowly eroding: declining salience, shrinking shelf presence and a gradual loss of relevance.

The ambition was to unlock Advil’s untapped potential, building it into a meaningfully different and superior brand identity – one that leverages the brand’s strong foundations in powerful, fast relief of tough pain while defying tired category tropes – establishing something that could go beyond short-term activation to create transformative and enduring impact.

The work was anchored in a deep consumer understanding of Advil’s audience, who defines pain as tough and disruptive. Those consumers don’t just feel pain physically, they feel it emotionally. Pain disrupts their plans, threatens their important moments, triggers anxiety about what they might miss. They want reassurance, but they also want to feel that a brand understands what they’re going through – a need many consumers feel isn’t met, particularly Gen-Z, 70% of whom feel they’re not believed when they’re in pain. 

Advil stepped into this gap with a complete programme: 

• A modernised Holistic Brand Language unifying the brand across touchpoints globally;
• A new science visualisation approach that replaced clinical jargon with consumer-friendly, visually impactful storytelling elevating product superiority;
• A redesigned pack system that transformed shelf presence, with IPSOS-tested results confirming the step change: +112.5% appeal, +82% perceived efficacy, and +67% purchase interest versus the prior design;
• A shift towards building cultural relevance – through fashion collaborations with Anya Hindmarch, festival activations including Release Athens, sport partnerships and creator partnerships on TikTok reaching new communities;
• And in specific challenger markets, Big Little Emergencies, a campaign platform that brought the emotional insight to life through depicting pain with the emotional scale consumers give it – with exaggerated pain metaphors and dramatized consequences anchored in the FOMO on the moments that matter – activated with a distinctive treatment unlike anything else in consumer health advertising. 

Within twelve months, the transformation yielded impressive results. In APAC, results in activation markets included penetration growth of +1.3% in a declining category, market share gains, sales growth ahead of the category, a 1.1pt increase in Demand Power and improvements across all brand equity metrics. Leveraging key elements of the work to more impactfully communicate on the brand’s core also drove growth more than 2x the category in markets across Europe & North America.  

Before this work, Advil was a product with superior strength, but no global identity. After it, Advil is a brand that consumers in more markets around the world recognise, remember, and choose — because it means something different from everything else on the shelf. The product truth remains the foundation. But the brand now communicates that truth through a unified identity, a distinctive emotional territory, and a visual language that travels globally. 

That is not a relaunch. That is a transformation.